Communiqués Outlook Therapeutics, Inc.

Actions

OTLK

US69012T3059

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 06/07/2026			Varia. 5j.	Varia. 1 janv.
1,420 ^USD	-2,07%		-15,98%	-10,13%

29/06	Outlook Therapeutics se met à nouveau en conformité avec le Nasdaq	MT
16/06	Outlook Therapeutics, Inc. annonce l'acceptation par la FDA du nouveau dépôt de sa demande de licence biologique pour l'ONS-5010/LYTENAVA (bevacizumab-vikg) dans le traitement de la DMLA humide	CI

Communiqués

17/06	Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA as a Treatment for Wet AMD	AQ
16/06	Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD	AQ
01/06	Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)	AQ
28/05	Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	AQ
26/05	Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)	AQ
15/05	Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update	AQ
23/04	Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering	AQ
22/04	Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	AQ
21/04	Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)	AQ
07/04	Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA	AQ
25/03	Outlook Therapeutics Announces Closing of $5.0 Million Public Offering	AQ
24/03	Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering	AQ
23/03	Outlook Therapeutics Announces Proposed Public Offering	AQ
16/03	Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note	AQ
05/03	Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)	AQ
19/02	Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland	AQ
17/02	Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update	AQ
11/02	Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter	AQ
06/01	Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development	AQ
31/12	Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD	AQ
29/12	Outlook Therapeutics Announces New Employment Inducement Grants	AQ
26/12	Outlook Therapeutics Announces New Employment Inducement Grants	AQ
22/12	Outlook Therapeutics Reports Financial Results for Fiscal Year 2025	AQ
19/12	Outlook Therapeutics Reports Financial Results for Fiscal Year 2025	AQ
24/11	Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference	AQ